#255 ‒ Latest therapeutics in CVD, APOE’s role in Alzheimer’s disease and CVD, familial hypercholesterolemia, and more | John Kastelein, M.D., Ph.D.
“One of the things that is so dangerous about this disorder is that the plaque that you get in FH is a soft plaque.” —John Kastelein
More hype than substance: erythritol and cardiovascular risk
A newly-published study caught public attention by reporting an association between the common sweetener erythritol and increased risk of heart attack and stroke, but there’s more to the story.
#240 ‒ The confusion around HDL and its link to cardiovascular disease | Dan Rader, M.D.
“HDL cholesterol itself is not directly and causally protective against atherosclerotic cardiovascular disease.” —Dan Rader
#230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more | Erin Michos, M.D.
“How we live the first half of our lives really influences our freedom for morbidity and mortality the second half of our lives.” —Erin Michos
Reassuring new data on statin-induced Lp(a) elevation
Statin therapy is known to raise Lp(a) particle concentration in some patients, but how does this impact the overall effect of these medications on ASCVD risk?
#229 ‒ Understanding cardiovascular disease risk, cholesterol, and apoB
“Not everybody dies from atherosclerosis, but… everybody dies with it.” —Peter Attia
The genetics of PCSK9i nonresponders
A recent case study shines light on why some individuals are resistant to PCSK9 inhibitors.